Physiometrix submits anaesthesia monitor to FDA:
This article was originally published in Clinica
Executive Summary
Physiometrix has submitted a 510(k) marketing application to the US FDA for its PSA 5000 next generation device for monitoring and managing a patient's level of consciousness while under anaesthesia. The PSA 5000 is more powerful, cost effective and ergonomic than its predecessor, the PSA 4000, said the North Billerica, Massachusetts company. "We believe this next generation technology, with several new features, will further differentiate us from our competition," added John Williams, the firm's president and CEO.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.